• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

    10/9/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    • By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette.
    • The brand's new HA5® moisturizer is designed to support the skin barrier and microbiome for bouncy, dewy, and soft skin.

    IRVINE, Calif., Oct. 9, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the rollout of SkinMedica®'s reimagined packaging—a modernized look that elevates the consumer experience while advancing sustainability. The updated design features a refreshed logo, luxe copper accents, and intuitive navigation cues that make it easier for consumers to select the right products.

    "As a leader in professional skincare, SkinMedica® is committed to delivering not only innovative formulas but also thoughtful design that meets the needs of today's consumers," said Glen Curran, Senior Vice President, U.S. Allergan Aesthetics. "The refreshed packaging represents the next chapter of SkinMedica®, bringing clarity, confidence, and sustainability to every touchpoint."

    Expanded Benefits of the Packaging Redesign:

    • Modern, luxe packaging that guides consumers – A refreshed logo, simplified layout, clean typography, and luxe copper accents bring clarity and confidence to product selection. At the same time, intuitive design and color cues make product navigation easier than ever.
    • Lower impact, same performance – Ninety percent of packaging components by weight and 100% of secondary cartons are recyclable, contributing to a 71% reduction in landfill waste (over 550,000 pounds annually*).1 These improvements lay the groundwork for innovation that supports both sustainability and the skincare routines of tomorrow.
    • Upgrades to TNS® Advanced+ Serum – A new separate dual-pump system improves reliability and consistency, paired with an enhanced design that provides better dispensing control.

    Debuting alongside the packaging redesign is the launch of the SkinMedica® HA5® Hydra Collagen Water Burst Moisturizer, a first-of-its-kind formula that quenches skin with up to 24-hour hydration while supporting a healthy skin barrier and microbiome. Designed to layer effortlessly with the HA5® Hydra Collagen Replenish + Restore Hydrator for even deeper hydration, this moisturizer marks the latest milestone in the brand's hydration-driven collection.

    Key Ingredients and Benefits:

    • HA5® Hydra Collagen Complex – A proprietary blend of five forms of hyaluronic acid plus vegan Hydra Collagen that delivers immediate hydration and smoothness.
    • Microbiome Barrier Complex – An advanced nutrient system with prebiotics, a plant-based carbohydrate and lactobacillus ferment, that helps support the skin barrier, maintain the skin's natural microbiome, and protect the skin from environmental aggressors.
    • Innovative Water-Burst Formula – Unique cascading emollient blend creates the water burst sensation with a lightweight, non-greasy texture, leaving skin feeling hydrated.

    "Most people experience dry skin at some point, but the issue can become more pronounced with age. As natural levels of hyaluronic acid and collagen decline, and nutrient flow between skin layers slows, the skin's ability to retain moisture diminishes," said Dr. Mona Gohara, board-certified dermatologist. "While many moisturizers offer temporary relief, the SkinMedica® HA5® Hydra Collagen Water Burst Moisturizer goes further—delivering up to 24 hours of hydration and boosting moisture levels by 25% after a single application1. It's a meaningful new option I can share with patients seeking dewy, resilient, and healthy-looking skin."

    In addition to the moisturizer, the following products will receive immediate upgrades: TNS® Advanced+ Serum, Even & Correct Advanced Brightening Treatment, AHA/BHA Exfoliating Cleanser, and Essential Defense Mineral Shield™ Broad Spectrum SPF 35 Sunscreen. All remaining SkinMedica® products will transition to the new packaging over the course of the next year.

    SkinMedica® HA5® Hydra Collagen Water Burst Moisturizer ($78) is available for purchase at SkinMedica.com, and through a network of licensed physicians and medically supervised spas. Consumers can build their complete HA5® routine by pairing the moisturizer with the HA5® Hydra Collagen Replenish + Restore Hydrator and HA5® Hydra Collagen Hydrating Foaming Cleanser for comprehensive hydration support.

    For a professional boost, ask your DiamondGlow® provider about incorporating HA5® Hydra Collagen products into your next in-office treatment. To find a provider, visit DiamondGlow.com.

    BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES 

    Approved Uses

    BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, frown lines between the eyebrows, and vertical bands connecting the jaw and neck (platysma bands) in adults.

    IMPORTANT SAFETY INFORMATION

    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands.

    BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

    Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

    Do not receive BOTOX® Cosmetic if you are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.

    Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX® Cosmetic.

    Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).

    Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.

    Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners.

    Other side effects of BOTOX® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes.

    For more information, refer to the Medication Guide or talk with your doctor.

    To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.

    Please see BOTOX® Cosmetic full Product Information, including Boxed Warning and Medication Guide.

    To learn more and earn points on your favorite aesthetic treatments, including SkinMedica®, join Allē, the number one aesthetics loyalty program, at Alle.com.

    About Allergan Aesthetics

    At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

    Forward-Looking Statements

    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

    DiamondGlow® Important Information 

    Uses

    The DiamondGlow® device is a general dermabrasion device that gently removes the top layer of skin and delivers topical cosmetic serums onto the skin.

    Important Safety Information

    The DiamondGlow® treatment is not for everyone. You should not have a DiamondGlow® treatment if you have compromised skin quality. Tell your provider if you are pregnant or lactating, or if you have any medical conditions, including allergies, and if you are using topical medications on the area to be treated.

    Typical side effects include a scratchy, stinging sensation during the treatment and temporary tightness, redness or slight swelling after the treatment. Rare serious side effects may also occur and include severe skin irritation and allergic reactions.

    SkinMedica® Pro-Infusion Serums Disclaimer 

    SkinMedica® Pro-Infusion Serums are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These products are not intended to be drugs that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.

    Please talk to your provider for additional information.

    SkinMedica® Important Information 

    Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA. 

    SkinMedica® Essential Defense Mineral Shield™ Broad Spectrum SPF 35 Sunscreen is an over-the-counter drug product that is formulated and marketed pursuant to the FDA's governing regulations set forth at 21 CFR Part 352.

    For more information, please talk to your provider or visit SkinMedica.com and DiamondGlow.com. To report an adverse reaction, please call Allergan at 1-800-433-8871.

    References:  

    1. Data on file at SkinMedica®

      *Based on forecasted 2026 volumes.

      "Widely Recyclable" = 60% of the population must have access to recycling infrastructure that accepts those components AND that infrastructure captures and sorts those components successfully.

    Investors:

    Liz Shea

    [email protected]

    (847) 935-2211

    Media:

    Ember Garrett

    [email protected]

    (714) 246-3525

    Allergan Aesthetics (PRNewsfoto/AbbVie)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/skinmedica-debuts-reimagined-packaging-and-unveils-new-ha5-hydra-collagen-water-burst-moisturizer-302579065.html

    SOURCE AbbVie

    Get the next $ABBV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    10/1/2025Buy → Hold
    HSBC Securities
    9/17/2025$270.00Hold → Buy
    Berenberg
    8/12/2025$231.00Overweight
    Piper Sandler
    8/7/2025$214.00Neutral → Outperform
    Daiwa Securities
    5/14/2025$205.00Buy → Neutral
    Citigroup
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    12/10/2024$191.00Neutral
    BofA Securities
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    More analyst ratings

    $ABBV
    SEC Filings

    View All

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    10/3/25 4:09:03 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    9/11/25 7:30:54 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by AbbVie Inc.

    144 - AbbVie Inc. (0001551152) (Subject)

    8/22/25 6:02:07 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

    By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette. The brand's new HA5® moisturizer is designed to support the skin barrier and microbiome for bouncy, dewy, and soft skin.IRVINE, Calif., Oct. 9, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the rollout of SkinMedica®'s reimagined packaging—a modernized look that elevates the consumer experience while advancing sustainability. The updated design features a refreshed logo, luxe copper accents, and intuitive navigation cues that make it easier for consumers to select the right products. "As a lead

    10/9/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

    OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total unilateral score compared to placebo.1The trial also met all six secondary endpoints.2Results from safety analyses were generally consistent with the well-established safety profile of onabotulinumtoxinA.1NORTH CHICAGO, Ill., Oct. 6, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared to placebo for the treatment of upper limb essential tremor. The study met its prim

    10/6/25 9:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Third-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –

    10/2/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbbVie downgraded by HSBC Securities

    HSBC Securities downgraded AbbVie from Buy to Hold

    10/1/25 12:17:59 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie upgraded by Berenberg with a new price target

    Berenberg upgraded AbbVie from Hold to Buy and set a new price target of $270.00

    9/17/25 7:51:43 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler resumed coverage on AbbVie with a new price target

    Piper Sandler resumed coverage of AbbVie with a rating of Overweight and set a new price target of $231.00

    8/12/25 8:00:24 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Quaggin Susan E

    4 - AbbVie Inc. (0001551152) (Issuer)

    10/2/25 5:00:41 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Alpern Robert J

    4 - AbbVie Inc. (0001551152) (Issuer)

    10/2/25 5:00:17 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rapp Edward J

    4 - AbbVie Inc. (0001551152) (Issuer)

    10/2/25 5:00:12 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie to Host Third-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –

    10/2/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share.   The cash dividend is payable November 14, 2025, to stockholders of record at the close of business on October 15, 2025.  Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We

    9/5/25 9:07:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Second-Quarter 2025 Financial Results

    Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to Acquired IPR&D and Milestones Expense   Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.631 Billion, an Increase of 9.5 Percent on a Reported Basis, or 9.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.423 Billion; Global Rinvoq Net Revenues Were $2.028 Billion; Global Humira Net Reven

    7/31/25 7:44:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care